Cardiol Therapeutics Inc
Cardiol Therapeutics Inc (CRDL) Covered Calls
As of September 25, 2026, CRDL has 2 covered call opportunities in the coming three months. Return ranges from 44.1 to 188.1% until expiration. Annualized return ranges from 90.9 to 388.0%. The nearest expiration is March 19, 2027. Maximum potential profit is $333.
Read more
Running CRDL covered calls helps you generate consistent income from Cardiol Therapeutics Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Cardiol Therapeutics Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best CRDL covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if CRDL stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling CRDL covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Cardiol Therapeutics Inc covered call is worth writing.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure.
Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Income-focused investors, long-term CRDL holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling CRDL covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Cardiol Therapeutics Inc covered calls come to you, already filtered for the metrics that matter.
Stock Statistics
- IndustryDrug Manufacturers - Specialty & Generic
- SectorHealthcare
- IV percentile38.49% Neutral
- Market cap (M$)200
- 52 weeks high-26.92%
- 52 weeks low94.32%
- Analyst recommendationStrong Buy
1.00 - Target price$7.91
362.57% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-12
- P/E—
- Future P/E—
- EPS (ttm)-0.25
- EPS growth next 5 years72.15%
As of September 25, 2026
| 2027-03-19 | 177 | 5.00 | 182.49 | 0.10 | 0.40 | 333.00 | 188.14 | 387.96 | -5.65 | +0.33 | 35 | 0.30 |
| 2027-03-19 | 177 | 2.50 | 41.24 | 0.05 | 0.55 | 78.00 | 44.07 | 90.87 | -2.82 | +0.46 | 933 | 0.50 |
As of September 25, 2026
Sell covered calls with the data behind you
Find the best CRDL covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.
Start your 14-day free trial→